Company research
DYADIC INTERNATIONAL INC
CIK 1213809Updated Sep 24, 2026
SecurityDYAI · NASDAQ · equity
Name history
CCP WORLDWIDE INC · through Nov 5, 2004
DYAI price & chart
Loading TradingView…
NASDAQ:DYAI on TradingView ↗About the company
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s Dapibus™ and C1 expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs.
In the news
Seeking Alpha
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript ↗
Dyadic signals 40% transferrin cost reduction as it pursues non-dilutive capital amid going concern disclosure ↗
Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript ↗
Recent filings
EFFECT filing
424B3 filing
S-1 filing
SCHEDULE 13G/A filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other Events
Items 1.01, 3.02, 8.01, 9.01
Show 5 more recent filings
424B5 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
144 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 9,945,725Source | 9,930,275Source | 8,219,236Source | 13,712,818Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,622,331Source | 6,506,750Source | 6,515,028Source | 5,794,272Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,090,297Source | 237,027Source | 466,159Source | 330,001Source |
| Assets, CurrentUSD | 9,896,653Source | 9,827,668Source | 8,067,335Source | 13,422,064Source |
| Prepaid Expense and Other Assets, CurrentUSD | 219,067Source | 303,066Source | 327,775Source | 392,236Source |
| Operating Lease, Right-of-Use AssetUSD | 38,535Source | 92,211Source | 141,439Source | — |
| Other Assets, NoncurrentUSD | 10,537Source | 10,396Source | 10,462Source | 6,045Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 8,713,315Source | 7,459,985Source | 2,340,651Source | 2,625,079Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 48,442Source | 42,090Source | 41,065Source | 40,817Source |
| Additional Paid in CapitalUSD | 113,564,991Source | 107,444,595Source | 105,044,756Source | 103,458,697Source |
| Retained Earnings (Accumulated Deficit)USD | -93,451,108Source | -86,086,480Source | -80,277,321Source | -73,481,860Source |
| Stockholders' Equity Attributable to ParentUSD | 1,232,410Source | 2,470,290Source | 5,878,585Source | 11,087,739Source |
| Liabilities and EquityUSD | 9,945,725Source | 9,930,275Source | 8,219,236Source | 13,712,818Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,687,271Source | 2,448,017Source | 2,251,781Source | 2,448,608Source |
| Operating Lease, Liability, CurrentUSD | 34,621Source | 54,249Source | 48,059Source | — |
| Accounts Payable, CurrentUSD | 852,024Source | 482,320Source | 656,445Source | 1,276,313Source |
| Operating Lease, Liability, NoncurrentUSD | — | 34,621Source | 88,870Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 967,974Source | 970,462Source | 1,057,164Source | 955,081Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 8,600,000Source | 9,287,575Source | — | — |
| Short-term InvestmentsUSD | 2,698,661Source | 2,780,825Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 930,183Source | 1,126,279Source | 1,244,121Source | 1,888,944Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 846,964Source | -219,425Source | 141,332Source | 83,265Source |
| Increase (Decrease) in Accounts PayableUSD | 314,451Source | -180,182Source | -651,168Source | -248,128Source |
| Deferred Income Tax Expense (Benefit)USD | — | 0Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -5,702,221Source | -3,974,806Source | -6,726,755Source | -8,083,775Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 82,085Source | -1,876,253Source | 7,449,896Source | -2,369,280Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 4,964,944Source | 5,848,577Source | 0Source | 543,591Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -653,251Source | -8,278Source | 720,756Source | -9,954,208Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,853,499Source | — | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 412,573Source | 257,778Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 930,183Source | 1,126,279Source | 1,244,121Source | 1,888,944Source |
| Amortization of Debt Issuance CostsUSD | 48,697Source | 63,021Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 8,600,000Source | 9,287,575Source | — | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | — | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -46,901Source | -22,561Source | -38,418Source | -49,918Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | 46,900Source | -22,561Source | -38,417Source | -49,918Source |
| Gain (Loss) on InvestmentsUSD | — | 60,977Source | — | — |
| Gain (Loss) on Sale of InvestmentsUSD | — | 62,642Source | 1,017,592Source | — |
| General and Administrative ExpenseUSD | 5,761,735Source | 6,134,773Source | 5,817,013Source | 6,421,505Source |
| Investment Income, InterestUSD | 284,085Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -7,364,628Source | -5,809,159Source | -6,795,461Source | -9,735,258Source |
| Nonoperating Income (Expense)USD | -171,812Source | 91,663Source | 1,434,278Source | 430,420Source |
| Operating Lease, ExpenseUSD | 119,537Source | 106,785Source | 72,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 250,000Source |
| Proceeds from Stock Options ExercisedUSD | 24,249Source | 24,251Source | 0Source | 543,591Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 3,090,345Source | 3,495,389Source | 2,898,806Source | 2,930,303Source |
| Cost of RevenueUSD | 2,319,860Source | 1,194,624Source | 1,975,849Source | 2,123,193Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -7,192,816Source | -5,900,822Source | -8,229,739Source | -10,165,678Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 250,000Source |
| Net Income (Loss) Attributable to ParentUSD | -7,364,628Source | -5,809,159Source | -6,795,461Source | -9,735,258Source |
| Earnings Per Share, BasicUSD per share | -0.23Source | -0.2Source | -0.24Source | -0.34Source |
| Earnings Per Share, DilutedUSD per share | -0.23Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 28,798,833Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 32,624,323Source | — | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 10,283,161Source | 9,396,211Source | 11,128,545Source | 13,095,981Source |
| Current Income Tax Expense (Benefit)USD | — | 0Source | 0Source | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | — | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -46,901Source | -22,561Source | -38,418Source | -49,918Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | 46,900Source | -22,561Source | -38,417Source | -49,918Source |
| Gain (Loss) on InvestmentsUSD | — | 60,977Source | — | — |
| General and Administrative ExpenseUSD | 5,761,735Source | 6,134,773Source | 5,817,013Source | 6,421,505Source |
| Income (Loss) Attributable to Parent, before TaxUSD | -7,364,628Source | -5,809,159Source | -6,795,461Source | -9,735,258Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -7,333,535Source | -5,757,824Source | -6,766,409Source | -9,828,427Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 416,686Source | 180,420Source |
| Investment Income, InterestUSD | 284,085Source | — | — | — |
| Nonoperating Income (Expense)USD | -171,812Source | 91,663Source | 1,434,278Source | 430,420Source |
| Operating Lease, ExpenseUSD | 119,537Source | 106,785Source | 72,000Source | — |
| Other General and Administrative ExpenseUSD | 889,987Source | — | — | — |
| Other IncomeUSD | — | — | 1,018,000Source | — |
| Research and Development ExpenseUSD | 2,154,666Source | 2,044,253Source | 3,297,266Source | 4,501,365Source |
Offerings
Registration 333-298902
Filing attachments
ex107.htm · S-1 · 2026-09-11
Calculation of Filing Fee Tables S-1 DYADIC INTERNATIONAL INC ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offer…
Read attachment ↗ex4-1.htm · 8-K · 2026-08-14
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗ex99-1.htm · 8-K · 2026-08-14
EX-99.1 8 ex99-1.htm EX-99.1 Exhibit 99.1 Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement JUPITER, FLA., August 13, 2026 -- Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced definitive agreements with an insti…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 DYADIC ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS ACCELERATING COMMERCIALIZATION MOMENTUM ACROSS KEY BUSINESS AREAS Dyadic to host earnings call on August 12 at 5:00 pm ET JUPITER, FL - August 12, 2026 - Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commerc…
Read attachment ↗ex99-1.htm · 8-K · 2026-07-24
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Dyadic Announces Continued Listing on The Nasdaq Capital Market JUPITER, Fla., July 24, 2026 - Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced that Nasdaq has confirmed that the Company has regained compliance with Nasdaq…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption Company’s C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial markets JUPITER, Fla., June 15, 2026 - Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolut…
Read attachment ↗